Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY
by Zacks Equity Research
The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.
Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy
by Zacks Equity Research
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position NVAX, HALO and BPMC to outperform.
Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand
by Zacks Equity Research
Gilead (GILD) lifts guidance for 2020, driven by increased Veklury (remdesivir) sales for COVID-19 as the pandemic worsens.
The Zacks Analyst Blog Highlights: Coca-Cola, Merck, Royal Dutch Shell, Gilead Sciences and FedEx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Coca-Cola, Merck, Royal Dutch Shell, Gilead Sciences and FedEx
Top Analyst Reports for Coca-Cola, Merck & Royal Dutch Shell
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Coca-Cola (KO), Merck (MRK), and Royal Dutch Shell (RDS.A).
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $62.52, marking a +0.92% move from the previous day.
Regeneron (REGN) Releases Initial Data on Cocktail for COVID-19
by Zacks Equity Research
Regeneron (REGN) reports positive initial data on its antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen.
FATE Surges More Than 152% in Three Months: Here's Why?
by Zacks Equity Research
FATE's recent positive pipeline updates have led to a significant upsurge in the stock price.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $58.49 in the latest trading session, marking a -1% move from the prior day.
Here's Why Lilly (LLY) Has Outperformed the Industry This Year
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make antibodies to treat COVID-19.
The Zacks Analyst Blog Highlights: PayPal, Shopify, BP p.l.c., Gilead Sciences and Southern Co
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PayPal, Shopify, BP p.l.c., Gilead Sciences and Southern Co
Top Research Reports for PayPal, Shopify & BP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PayPal Holdings (PYPL), Shopify (SHOP) and BP p.l.c. (BP).
Company News for Dec 17, 2020
by Zacks Equity Research
Companies In The News Are: GOOGL, LUV, TLRY, APHA, GLPG, GILD.
Gilead's (GILD) CAR T Cell Therapy Tecartus Wins EC Nod
by Zacks Equity Research
Gilead (GILD) company, Kite, gets conditional marketing authorization for CAR T cell therapy, Tecartus.
Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal
by Zacks Equity Research
Gilead (GILD) decides to not pursue FDA approval of filgotinib for the treatment of RA.
Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.
Lilly (LLY) Stock Up on Raised 2020 View, Upbeat 2021 Guidance
by Zacks Equity Research
Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $59.84, moving -1.51% from the previous trading session.
Glaxo's (GSK) Rukobia Gets CHMP Nod for Heavily Pre-Treated HIV
by Zacks Equity Research
Glaxo (GSK) receives positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rukobia for treating HIV-1 infection in heavily pre-treated adult HIV patients.
Gilead (GILD) to Buy MYR GmbH for EUR1.15 Billion in Cash
by Zacks Equity Research
Gilead (GILD) will purchase MYR GmbH for EUR1.15 billion and add HDV treatment Hepcludex to its portfolio.
Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $60.82 in the latest trading session, marking a -0.57% move from the prior day.
Fate (FATE) Surges on Favorable Phase I Data on FT596 at ASH
by Zacks Equity Research
Fate (FATE) stock up on positive data from its early-stage study on its NK cell product candidate at ASH.
Aligos (ALGS) Inks Collaboration With Merck for NASH Therapy
by Zacks Equity Research
Aligos (ALGS) signs an exclusive research collaboration agreement with Merck to discover and develop an oligonucleotide therapy for NASH. Shares rise.
Gilead's (GILD) Kite Presents Data on CAR T Cell Therapy at ASH
by Zacks Equity Research
Gilead (GILD) posts positive data on CAR T Cell Therapy Yescarta from multiple studies at ASH.